The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Cancer Research Institute announces 2025 recipients of cancer immunotherapy awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Alan Korman

Aviv Regev

Jeffrey C. Rathmell

The Cancer Research Institute announced the 2025 recipients of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology and the Frederick W. Alt Award for New Discoveries in Immunology.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Funding Opportunities

International Myeloma Society opens applications for over $3M in 2027 research funding

The International Myeloma Society, in partnership with the Paula and Rodger Riney Foundation, is accepting applications for more than $3 million in research funding through its 2027 Translational Research and Career Development awards. The awards support research to improve the prevention, early detection, diagnosis, and treatment of multiple myeloma and related plasma cell disorders, while developing the next generation of researchers in the field.
Clinical Roundup

Wistar Institute study identifies immunotherapy strategy for glioblastoma

Scientists at the Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. The researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and prevented them from coming back.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account